Community curated by people like you

Grand Canyon stories

Nov 3, 2026

Servier's $1.55 billion muscular dystrophy drug fails pivotal trial

Servier's sevasemten, acquired from Edgewise for $1.55 billion upfront in June 2026, failed its pivotal trial for muscular dystrophy just five months after the acquisition.

Nov 3, 2026·2 sources

00

Top claims

▪Servier purchased the experimental drug sevasemten from Edgewise Therapeutics in June 2026 for $1.55 billion in upfront cash, plus up to approximately $1 billion in potential milestones
▪The experimental drug sevasemten, originally developed by Edgewise Therapeutics, had previously demonstrated promising results in a smaller randomized clinical study conducted before Servier's 2026 acquisition of the drug
▪Servier's $1.55 billion acquisition of sevasemten failed its pivotal trial five months after the June 2026 deal with Edgewise Therapeutics was struck

Topics

Clinical trials Mergers and acquisitions Pharmaceutical Industry Rare diseases Mergers & acquisitions (M&A)Drug development Genetic diseases

Related entities